Integrating Omics to Advance Antiretroviral Pharmacology in Pregnancy: Dolutegravir‐Based Regimens as a Case Study
The Journal of Clinical Pharmacology · 2026-11 · 66 (11)
DOI: 10.1002/jcph.70324 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 01.11.2026. Verfasst von Ahizechukwu C Eke. Beteiligte Einrichtung: Division of Maternal Fetal Medicine & Clinical Pharmacology, Department of Gynaecology and Obstetrics, Johns Hopkins University School of Medicine, B…. Hauptthemen laut MEDLINE: Piperazines, Oxazines, Heterocyclic Compounds, 3-Ring, HIV Infections. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Eunice Kennedy Shriver National Institute of Child Health and Human Development, NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Dolutegravir is central to antiretroviral therapy in pregnancy, although conventional pharmacokinetic measures cannot fully explain variability in maternal cardiometabolic outcomes or fetal exposure. This narrative review proposes an integrated omics framework linking pharmacogenomics, transcriptomics, proteomics, and metabolomics with longitudinal pharmacokinetics and clinical phenotyping. Using dolutegravir as a case study, we examine genetic determinants of drug disposition, gestational changes in molecular pathways, and emerging evidence implicating adipose dysfunction, mitochondrial metabolism, lipid remodeling, and insulin resistance. We distinguish established pharmacokinetic findings from mechanistic hypotheses requiring pregnancy‐specific validation. Proposed studies combine serial maternal sampling, targeted placental and adipose investigations, and offspring follow‐up, while accounting for HIV, antiretroviral backbone, gestational physiology, and environmental confounding. Prespecified analyses, analytical validation, and independent replication are essential to avoid overinterpretation. Integrated omics should complement, not replace, pharmacometrics, ultimately identifying reproducible mechanisms and clinically useful biomarkers to inform individualized monitoring and treatment strategies while preserving dolutegravir's proven virologic benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Maternal Fetal Medicine & Clinical Pharmacology, Department of Gynaecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
ORCID-Profile: Ahizechukwu C Eke
Förderung
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Eke, A. C. (2026). Integrating Omics to Advance Antiretroviral Pharmacology in Pregnancy: Dolutegravir‐Based Regimens as a Case Study. The Journal of Clinical Pharmacology, 66(11). https://doi.org/10.1002/jcph.70324
Vancouver
Eke AC. Integrating Omics to Advance Antiretroviral Pharmacology in Pregnancy: Dolutegravir‐Based Regimens as a Case Study. The Journal of Clinical Pharmacology. 2026;66(11). doi:10.1002/jcph.70324
BibTeX
@article{Eke2026,
author = {Eke, Ahizechukwu C},
title = {Integrating Omics to Advance Antiretroviral Pharmacology in Pregnancy: Dolutegravir‐Based Regimens as a Case Study},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
volume = {66},
number = {11},
doi = {10.1002/jcph.70324}
}
EUVIMED